DPI‑4452 is a novel peptide‑based theranostic agent that targets Carbonic Anhydrase IX (CAIX), a protein highly expressed in hypoxic solid tumors such as clear cell renal cell carcinoma, colorectal cancer, and pancreatic cancer. It is designed for both PET imaging (with Gallium‑68) and targeted radionuclide therapy (with Lutetium‑177), offering a personalized approach to oncology.